10/12/2025
The Asian Working Group for Sarcopenia (AWGS) has updated its 2025 consensus, introducing new definitions, diagnostic criteria, and a stronger focus on muscle health promotion across the lifespan. 💪🏻
The 2025 updates are designed to make sarcopenia assessment more streamlined, consistent, and applicable to diverse Asian populations — with an emphasis on early detection starting from midlife.
🔍 Key updates include:
• Simplified diagnostic criteria: Sarcopenia is now defined as concurrent low muscle mass and low muscle strength.
• Removal of severity levels: Categories such as “severe sarcopenia” are removed, leaving at risk of sarcopenia, possible sarcopenia, and sarcopenia.
• Physical performance as outcome indicators rather than diagnostic criteria.
• Shift toward muscle health promotion, not just disease diagnosis and treatment.
• New cutoff values for adults aged 50–64, supporting earlier screening and prevention.
🤝 How InBody supports AWGS 2025:
• Accurate SMI measurement with InBody Body Composition Analyzers
• Age- and gender-based reference graphs in the InBody970S & BWA2.0S Evaluation Result Sheets
• Quick handgrip strength testing with the InGrip Handgrip Strength Dynamometer
• InGrip connects directly to InBody devices to record muscle strength as part of a complete sarcopenia assessment
With InBody Body Composition Analyzers and the InGrip Handgrip Strength Dynamometer, healthcare professionals now have a quick, precise, and evidence-based solution to assess skeletal muscle mass and muscle strength in line with AWGS 2025 recommendations.
🔗 Read our full blogpost to explore all the AWGS 2025 updates and how InBody simplifies sarcopenia assessment! Link to the blogpost is in our profile bio!